Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

Company Overview - Vor Bio is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases [3] - The company is advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization [3] Leadership Appointment - Adi Osovsky, S.J.D. has been appointed as General Counsel, bringing 17 years of experience in corporate counsel and law firm roles within the biotechnology and pharmaceutical sectors [1][2] - Dr. Osovsky previously served as Executive Vice President and Head of Legal & Corporate Secretary at iTeos Therapeutics, overseeing corporate legal and compliance activities [2] - Her experience includes senior legal roles at Sarepta Therapeutics, where she supported corporate transactions and governance during a period of rapid growth [2] Strategic Importance - The appointment of Dr. Osovsky is seen as crucial for Vor Bio's growth, particularly as the company advances its late-stage clinical programs [2] - The CEO, Jean-Paul Kress, emphasized that Dr. Osovsky's expertise in governance, compliance, and strategic transactions will be invaluable for the company's future [2]